Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,

Hugo F. Fernandez, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Selina M. Luger, MD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, Gordon W. Dewald, PhD, PhD, FACMG, Rhett P Ketterling, MD, John M. Bennett, MD, Jacob M. Rowe, MD, Hillard M. Lazarus, MD, FACP, Martin S. Tallman, MD

Blood (2011) 118 (21): 3619.

https://doi.org/10.1182/blood.V118.21.3619.3619

Published: 2011

Journal Articles

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Jacob M. Rowe, MD, Georgina Buck, Anthony V Moorman, MD, Martin S Tallman, MD, Susan M Richards, Ph.D, Adele K Fielding, MD, Ph.D, Alan K. Burnett, MD, FRCP, Ian M Franklin, MD, Peter H. Wiernik, MD, Hillard M Lazarus, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David I Marks, MD, Selina Luger, MD, Gordon W. Dewald, PhD, PhD, FACMG, Anthony H. Goldstone, FRCP, FRCPath

Blood (2008) 112 (11): 3314.

https://doi.org/10.1182/blood.V112.11.3314.3314

Published: 2008

Journal Articles

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

Elisabeth Paietta, Ph.D., Xiaochun Li, Ph.D., Sue Richards, Janis Racevskis, Ph.D., Gordon W. Dewald, PhD, PhD, FACMG, Jacob M. Rowe, MD, Martin S Tallman, Hillard M Lazarus, MD, Mark Litzow, M.D., Anthony H. Goldstone, FRCP, FRCPath, Peter H. Wiernik, MD

Blood (2008) 112 (11): 1907.

https://doi.org/10.1182/blood.V112.11.1907.1907

Published: 2008

Journal Articles

Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se.

Elisabeth Paietta, Xiaochun Li, Ph.D., Sue Richards, Janis Racevskis, Ph.D., Gordon W. Dewald, PhD, PhD, FACMG, Jacob M. Rowe, MD, Martin S Tallman, Hillard M Lazarus, MD, Mark R. Litzow, MD, Anthony H. Goldstone, FRCP, FRCPath, Peter Wiernik, MD

Blood (2008) 112 (11): 1500.

https://doi.org/10.1182/blood.V112.11.1500.1500

Published: 2008

Journal Articles

Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.

Kebede Hussein, MD, Rhett P. Ketterling, MD, Gordon W. Dewald, PhD, Rachael L. Hulshizer, Daniel G. Kuffel, Anne E. Wiktor, Daniel L. Van Dyke, PhD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 3504.

https://doi.org/10.1182/blood.V110.11.3504.3504

Published: 2007

Journal Articles

Peripheral Blood Cytogenetic Studies in Myelofibrosis: Overall Yield and Comparison with Bone Marrow Cytogenetic Studies

Kebede Hussein, MD, Rhett P. Ketterling, MD, Gordon W. Dewald, PhD, Daniel L. Van Dyke, PhD, Ruben Mesa, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 1547.

https://doi.org/10.1182/blood.V110.11.1547.1547

Published: 2007

Journal Articles

Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.

Clive S. Zent, MD, Nancy D. Bone, Timothy G. Call, MD, Tait D. Shanafelt, MD, Susan M. Geyer, PhD, Charla R. Secreto, Diane F. Jelinek, PhD, Gordon W. Dewald, PhD, Neil E. Kay, MD

Blood (2006) 108 (11): 2829.

https://doi.org/10.1182/blood.V108.11.2829.2829

Published: 2006

Journal Articles

Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.

Rebekah E. Browning, BA, David M. Lucas, PhD, Susan M. Geyer, PhD, Diane F. Jelinek, PhD, Renee C. Tschumper, Timothy G. Call, MD, Tait D. Shanafelt, MD, Clive S. Zent, MD, Nancy D. Bone, Gordon W. Dewald, PhD, Thomas S. Lin, MD, Nyla A. Heerema, PhD, Michael R. Grever, MD, Neil E. Kay, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2792.

https://doi.org/10.1182/blood.V108.11.2792.2792

Published: 2006

Journal Articles

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Azra Raza, MD, James E. Reeves, MD, Eric J. Feldman, MD, H. Joachim Deeg, MD, Luke Dreisbach, MD, Charles A. Schiffer, MD, Jamile M. Shammo, MD, Virginia M. Klimek, MD, Peter L. Greenberg, MD, John M. Bennett, MD, Gordon W. DeWald, PhD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RN,C, Robert D. Knight, MD, Alan F. List, MD

Blood (2006) 108 (11): 250.

https://doi.org/10.1182/blood.V108.11.250.250

Published: 2006

Journal Articles

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

Alan F. List, MD, Gordon W. Dewald, PhD, John M. Bennett, MD, Aristoteles Giagounidis, MD, Azra Raza, MD, Eric J. Feldman, MD, Bayard L. Powell, MD, Peter L. Greenberg, MD, Stephen D. Nimer, MD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RNC, Robert D. Knight, MD

Blood (2006) 108 (11): 251.

https://doi.org/10.1182/blood.V108.11.251.251

Published: 2006

Journal Articles

Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia.

Tait D. Shanafelt, MD, Nancy D. Bone, Susan M. Geyer, PhD, Betsy LaPlant, Thomas E. Witzig, MD, Susan Schwager, Gordon W. Dewald, PhD, Greg S. Nowakowski, MD, Renee C. Tschumper, MD, Clive S. Zent, MD, Timothy G. Call, MD, Diane F. Jelinek, PhD, Neil E. Kay, MD

Blood (2006) 108 (11): 2776.

https://doi.org/10.1182/blood.V108.11.2776.2776

Published: 2006

Journal Articles

Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.

Animesh D. Pardanani, MD, PhD, Rhett P. Ketterling, MD, Chin-Yang Li, MD, Alexandra P. Wolanskyj, MD, Michelle A. Elliott, MD, John K. Camoriano, MD, Joseph H. Butterfield, MD, Gordon W. Dewald, PhD, Ayalew Tefferi, MD

Blood (2005) 106 (11): 2590.

https://doi.org/10.1182/blood.V106.11.2590.2590

Published: 2005

Journal Articles

Ferrochelatase Mutation Screening by Denaturing High Performance Liquid Chomatography in Idiopathic Acquired Sideroblastic Anemia (Refractory Anemia with Ringed Sideroblasts) and Erythrocytic Protoporphyria.

Kathleen A. Hecksel, BS, Gordon W. Dewald, PhD, David P. Steensma, MD

Blood (2005) 106 (11): 3735.

https://doi.org/10.1182/blood.V106.11.3735.3735

Published: 2005

Journal Articles

Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).

Gordon W. Dewald, PhD, Stephanie Fink, Stephanie Smoley, Kimberly Stockero, Sarah Paternoster, Schwager Susan, Erik C. Thorland, PhD, Daniel L. Van Dyke, PhD, Tait Shanafelt, MD, Clive Zent, MD, Timothy Call, MD, Neil Kay, MD

Blood (2005) 106 (11): 3255.

https://doi.org/10.1182/blood.V106.11.3255.3255

Published: 2005

Journal Articles

Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.

Michael R. Grever, MD, David M. Lucas, PhD, Gordon W. Dewald, PhD, Donna S. Neuberg, PhD, Ian W. Flinn, MD, PhD, Martin S. Tallman, MD, John G. Gribben, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3487.

https://doi.org/10.1182/blood.V104.11.3487.3487

Published: 2004

Journal Articles

Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used.

David M. Lucas, PhD, Gordon W. Dewald, PhD, Donna S. Neuberg, PhD, John C. Byrd, MD, Gerard Lozanski, MD, Jennifer Harbison, Kammy D. Cunningham, Ian W. Flinn, MD, PhD, Martin S. Tallman, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 949.

https://doi.org/10.1182/blood.V104.11.949.949

Published: 2004

Journal Articles

Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment.

Shinichi Kitada, PhD, John C. Reed, MD PhD, David M. Lucas, PhD, Donna S. Neuberg, PhD, John G. Gribben, MD, Gordon W. Dewald, PhD, Ian W. Flinn, MD PhD, Martin S. Tallman, MD, John C. Byrd, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 956.

https://doi.org/10.1182/blood.V104.11.956.956

Published: 2004

Journal Articles

Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.

Neil E. Kay, MD, Susan M. Geyer, PhD, Thomas Lin, MD, Timothy G. Call, MD, Diane F. Jelinek, PhD, Nancy D. Bone, MS, Gordon W. Dewald, PhD, Nyla L. Heerema, PhD, Renee Tschumper, BS, L. Smith, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 339.

https://doi.org/10.1182/blood.V104.11.339.339

Published: 2004

Journal Articles

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Ian W. Flinn, MD, PhD, Elizabeth Kumm, MS, Michael R. Grever, MD, Donna Neuberg, ScD, Gordon W. Dewald, PhD, John M. Bennett, MD, Elisabeth M. Paietta, PhD, Mohamad A. Hussein, MD, Dennis F. Moore, Jr., MD, Martin S. Tallman, MD

Blood (2004) 104 (11): 475.

https://doi.org/10.1182/blood.V104.11.475.475

Published: 2004

Journal Articles

Familial Chronic Lymphocytic Leukemia(CLL): The Mayo Clinic Experience.

Tufia C. Haddad, MD, Tait D. Shanafelt, MD, Susan L. Slager, PhD, Robert L. Phyliky, MD, Clive S. Zent, MD, Gordon W. Dewald, PhD, Neil E. Kay, MD, Timothy G. Call, MD

Blood (2004) 104 (11): 1906.

https://doi.org/10.1182/blood.V104.11.1906.1906

Published: 2004

NARROW

Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se.

Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.

Peripheral Blood Cytogenetic Studies in Myelofibrosis: Overall Yield and Comparison with Bone Marrow Cytogenetic Studies

Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.

Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia.

Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.

Ferrochelatase Mutation Screening by Denaturing High Performance Liquid Chomatography in Idiopathic Acquired Sideroblastic Anemia (Refractory Anemia with Ringed Sideroblasts) and Erythrocytic Protoporphyria.

Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).

Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.

Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used.

Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment.

Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.

Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.

Familial Chronic Lymphocytic Leukemia(CLL): The Mayo Clinic Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only